Europe Bioreactors Market to accrue $ 850 Mn by 2025

March 06, 2020


The research report titled ‘Europe Bioreactors Market Size By Technology, Molecule, End-use, Cell, Industry Analysis Report, Country Outlook, Application Potential, Competitive Market Share & Forecast, 2018 – 2025’, which is available with Market Study Report LLC, highlights key industry trends and growth prospects of Europe bioreactors market.
 

According to the report, Europe bioreactors market is expected to amass USD 850 million by the year 2025. Advancements in technology pertaining to processing and design of bioreactors is a major factor driving the market growth. Development of single-use systems and process analytical technology in bioreactors is also aiding the expansion of Europe bioreactors market. Moreover, rising elderly population, increased pervasiveness of chronic diseases, and surging investments towards technological improvements have enhanced the growth of biopharmaceutical industry, which in turn is stimulating the bioreactors market outlook.
 

Increasing orphan drugs development has allowed for enhancements in patient monitoring, diagnosis, treatment, and therapeutic solutions. This factor along with favorable FDA approvals for orphan drugs is fostering the demand for bioreactors across Europe. However, factors such as limited storage capacity, strict regulations regarding single-use bioreactors, and high risk of leaching may hinder the overall market growth. Adding to this, rising environmental concerns with respect to large-scale disposal of plastic derivatives may further inhibit Europe bioreactors market share.
 

The report cites that bacterial cells market segment is expected to grow with a CAGR of 16.9% during 2018-2025. Bacterial cells offer better strength and are not susceptible to damage. Moreover, these cells offer high mass transfer, permit rapid metabolism, and improve microbial cell cultivation. Bacterial cells are also used in the production recombinant proteins and thus, aforementioned factors are stimulating the industry outlook.
 

In terms of technology, the report states that stirred SUBs market segment is presumed to expand with a CAGR of 17.1% between 2018 and 2025. The stirred SUBs are extensively used in vaccines, for producing monoclonal antibodies, and for mammalian cell cultures. Moreover, low risk of cross contamination along with short turnaround times associated with stirred SUBs technology has enhanced its adoption rate in biotechnological processes, which in turn is favoring the segmental share.
 

Citing the end-use landscape, Europe bioreactors market from biopharma manufacturers segment was worth USD 88.9 million in the year 2018 and will witness lucrative growth in the forthcoming years. Proliferating biopharmaceutical pipeline drugs along with rising development of new manufacturing facilities is propelling the market growth.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2506081/
 

Considering the geographical landscape, the report cites that Germany bioreactors industry held 25.9% share in the year 2018 and is predicted to experience constant growth during the estimated timeframe. Rising number of biopharmaceutical companies has enabled the development of innovative medicines. This factor along with rising collaborations of biopharma companies with patients, academic institution, and venture capital firms are facilitating the business scenario in Germany.
 

The prominent companies operating in Europe bioreactors market are Thermo Fisher Scientific, Inc., Solaris Biotech Solutions, Sartorius Stedim Biotech Group, Pierre Guerin Sas, Merck Group, GEA Group Aktiengesellschaft, GE Healthcare, Eppendorf AG, CerCell Aps, Cellexus Ltd., Bbi-biotech, and Applikon Biotechnology, Inc.


Frequently Asked Questions (FAQ) :

Advancements in technology pertaining to processing and design of bioreactors is a major factor driving the growth of Europe bioreactors market. Development of single-use systems and process analytical technology in bioreactors is also aiding the expansion of Europe bioreactors market. Moreover, rising elderly population, increased pervasiveness of chronic diseases and surging investments towards technological improvements have enhanced the growth of biopharmaceutical industry, which in turn is stimulating the bioreactors market outlook. Increasing orphan drugs development has allowed for enhancements in patient monitoring, diagnosis, treatment, and therapeutic solutions. This factor along with favorable FDA approvals for orphan drugs is fostering the demand for bioreactors across Europe.
The report states that stirred SUBs market segment is presumed to expand with a CAGR of 17.1% between 2018 and 2025. The stirred SUBs are extensively used in vaccines, for producing monoclonal antibodies, and for mammalian cell cultures. Moreover, low risk of cross contamination along with short turnaround times associated with stirred SUBS technology has enhanced its adoption rate in biotechnological processes, which in turn is favoring the market outlook.
The report cites that Germany bioreactors industry held 25.9% share in the year 2018 and is predicted to experience constant growth during the estimated timeframe. Rising number of biopharmaceutical companies has enabled the development of innovative medicines. This factor along with rising collaborations of biopharma companies with patients, academic institution, and venture capital firms are facilitating the business scenario in Germany.
The prominent companies operating in Europe bioreactors market are Thermo Fisher Scientific, Inc., Solaris Biotech Solutions, Sartorius Stedim Biotech Group, Pierre Guerin Sas, Merck Group, GEA Group Aktiengesellschaft, GE Healthcare, Eppendorf AG, CerCell Aps, Cellexus Ltd., Bbi-biotech, and Applikon Biotechnology, Inc.